Attached files
| file | filename |
|---|---|
| EX-2.1 - EX-2.1 - ANGIOTECH PHARMACEUTICALS INC | a12-26526_1ex2d1.htm |
| EX-31.2 - EX-31.2 - ANGIOTECH PHARMACEUTICALS INC | a12-26526_1ex31d2.htm |
| EX-10.1 - EX-10.1 - ANGIOTECH PHARMACEUTICALS INC | a12-26526_1ex10d1.htm |
| EX-32.2 - EX-32.2 - ANGIOTECH PHARMACEUTICALS INC | a12-26526_1ex32d2.htm |
| EX-32.1 - EX-32.1 - ANGIOTECH PHARMACEUTICALS INC | a12-26526_1ex32d1.htm |
| EX-31.1 - EX-31.1 - ANGIOTECH PHARMACEUTICALS INC | a12-26526_1ex31d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 2)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2012
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 000-30334
Angiotech Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
British Columbia, Canada |
|
98-0226269 |
|
(State or Other Jurisdiction of |
|
(I.R.S. Employer |
|
|
|
|
|
1618 Station Street |
|
V6A 1B6 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (604) 221-7676
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer o |
|
Accelerated filer o |
|
|
|
|
|
Non-accelerated filer x |
|
Smaller reporting company o |
|
(Do not check if a smaller reporting company) |
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
12,526,702 Common Shares, no par value, as of August 14, 2012
EXPLANATORY NOTE
This Amendment No. 2 to Angiotech Pharmaceutical, Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012, filed on August 14, 2012, as amended by Amendment No.1 filed on September 13, 2012 (as amended, the “Form 10-Q”) is being filed solely to file revised versions of Exhibit 2.1 and Exhibit 10.1.
Other than the changes described above, no other modifications or updates have been made to our Form 10-Q. In addition, this Amendment No. 2 does not reflect any subsequent events occurring after the August 14, 2012 original filing date of our Form 10-Q.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Item 6. Exhibits
Incorporated by reference to the Exhibit Index following the signature page to this Amendment No. 2.
|
|
Angiotech Pharmaceuticals, Inc. | |
|
|
(Registrant) | |
|
|
| |
|
Date: November 13, 2012 |
By: |
/S/ K. THOMAS BAILEY |
|
|
|
K. Thomas Bailey |
|
|
|
Chief Executive Officer |
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
Location |
|
|
|
|
|
|
|
2.1 |
|
Asset Sale and Purchase Agreement by and among Angiotech Pharmaceuticals, Inc., Surgical Specialties Puerto Rico, Inc., Quill Medical, Inc., Ethicon, Inc. and Ethicon, LLC dated as of April 4, 2012* |
|
Filed herewith |
|
|
|
|
|
|
|
10.1 |
|
Co-Exclusive Manufacturing and Supply Agreement by and among Angiotech Pharmaceuticals, Inc., Surgical Specialties Puerto Rico, Inc., Angiotech Puerto Rico, Inc., Angiotech International AG, Quill Medical, Inc. and Ethicon, LLC dated as of April 4, 2012* |
|
Filed herewith |
|
|
|
|
|
|
|
10.2 |
|
Third Amendment, dated August 13, 2012 to the Credit Agreement dated May 12, 2011 by and among Angiotech Pharmaceuticals, Inc., as Parent, the subsidiaries of the Parent listed as Borrowers on the signature pages thereto, as Borrowers, the Lenders signatory thereto, as Lenders, and Wells Fargo Capital Finance, LLC, as Arranger and Administrative Agent for the Lenders. |
|
Previously filed |
|
|
|
|
|
|
|
31.1 |
|
Certification of CEO Pursuant to Securities Exchange Act Rules 13a-14 and 15d-14 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
Filed herewith |
|
|
|
|
|
|
|
31.2 |
|
Certification of CFO Pursuant to Securities Exchange Act Rules 13a-14 and 15d-14 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
Filed herewith |
|
|
|
|
|
|
|
32.1 |
|
Certification of CEO Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
Filed herewith |
|
|
|
|
|
|
|
32.2 |
|
Certification of CFO Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
Filed herewith |
|
|
|
|
|
|
|
101.INS |
|
XBRL Instance Document |
|
Previously furnished |
|
|
|
|
|
|
|
101.SCH |
|
XBRL Taxonomy Extension Schema Document |
|
Previously furnished |
|
|
|
|
|
|
|
101.CAL |
|
XBRL Taxonomy Extension Calculation Linkbase Document |
|
Previously furnished |
|
|
|
|
|
|
|
101.DEF |
|
XBRL Taxonomy Extension Definition Linkbase Document |
|
Previously furnished |
|
|
|
|
|
|
|
101.LAB |
|
XBRL Taxonomy Extension Label Linkbase Document |
|
Previously furnished |
|
|
|
|
|
|
|
101.PRE |
|
XBRL Taxonomy Extension Presentation Linkbase Document |
|
Previously furnished |
* Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a request for confidential treatment